Established in 2012, Chengdu Seamaty Technology Co., Ltd is a professional high-tech enterprise located in Chengdu, Sichuan Province, China. We are specialized in the R&D, production, marketing and service of in vitro diagnostic devices and reagents, we have 9 years of experience in POCT products and have good reputation in this field. We have more than 200 employees, including 63 professional engineers with high education and 72 skilled workers with strict training. We also boast complete production lines and established standard GMP factory and introduced a variety of advanced equipment which ensures high productivity and efficient production. With our experienced and professional team, we have exported our products to more than 80 countries and regions all over the world. All our products are manufactured with advanced equipment and strict QC procedures to make sure that each product can meet quality requirements of customers. Besides, all of our products have been strictly inspected before shipment. Our products have attained CE certificate and passed German T U V I S O 1 3 4 8 5 quality management system certification. As a high-tech enterprise, Seamaty has registered invention patents, utility model patents appearance patents with completely intellectual property rights. We welcome customers, business associations and friends from all over the world to contact us and seek cooperation for mutual benefits.
Instruments
Others
Here is an opportunlty to contact and meet other potentlal companles or partners.
If you are interested in booking a stand at CACLP, please leave your details below and one of our representatives will be in touch soon.
Copyright © 2024 GL events Ruihe (Shanghai) Exhibition Co., Ltd. All Rights Reserved. ( 沪ICP备12004745号-1 )
We deliver the latest IVD news straight to your inbox. Stay in touch with CACLP News.
sign-up for our newsletter today.
To ensure our newsletter hit your inbox, make sure to add @caclp.com to your safe senders list. And, as always, feel free to contact
us with any questions and thanks again for subscribing.
Go back
